Meeting
2020 ASCO Virtual Scientific Program
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
Authors
James L Januzzi
Massachusetts General Hospital, Boston, MA
James L Januzzi , Joseph Garasic , Scott Kasner , Vickie McDonald , Mark C Petrie , Jonathan Seltzer , Michael J. Mauro , Kevin Croce , Ellin Berman , Michael W.N. Deininger , Andreas Hochhaus , Javier Pinilla-Ibarz , Franck E. Nicolini , Dong-Wook Kim , Daniel J. DeAngelo , Hagop M. Kantarjian , Jing Xu , Shouryadeep Srivastava , Daniel Naranjo , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT01207440
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7550)
DOI
10.1200/JCO.2020.38.15_suppl.7550
Abstract #
7550
Poster Bd #
323
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes
Poster
2017 ASCO Annual Meeting
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
First Author: Hagop M. Kantarjian
Poster
2017 ASCO Annual Meeting
Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.
First Author: Martin Mueller
Poster
2015 ASCO Annual Meeting
Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials.
First Author: Hanna Jean Khoury